Zydus Cadila gets USFDA nod for generic Schizophrenia drug

Zydus Cadila gets USFDA nod for generic Schizophrenia drug

117
USFDA
Picture: Pixabay

Last Updated on December 13, 2021 by The Health Master

Drug firm Zydus Cadila on Friday said it has received approval from the US health regulator to market generic drug Cariprazine capsules, which are used in the treatment of schizophrenia.

The company’s subsidiary has received tentative approval from the US Food and Drug Administration (USFDA) for Cariprazine capsules in the strengths of 1.5 mg, 3 mg, 4.5 mg, and 6 mg, the drug firm said in a statement.

Cariprazine is an atypical antipsychotic medication used for the treatment of schizophrenia and the acute treatment of manic or mixed episodes associated with bipolar disorder.

The drug production will be done at the group’s formulation manufacturing facility in the Special Economic Zone (SEZ), Ahmedabad.

The group now has 325 approvals and has so far filed over 400 ANDAs (Abbreviated New Drug Applications) since the commencement of the filing process in FY 2003-04, the drug maker noted.

Alembic gets USFDA tentative nod for drug for high BP

Biocon gets USFDA nod for Mycophenolic Acid

Morepen gets USFDA nod for anti-allergy drug

USFDA approves new drug to help identify cancer lesions

USFDA grants accelerated approval for Vosoritide for injection

Zydus Cadila gets USFDA nod to market generic Cancer drug in US

High Court quashed the criminal complaint of alleged NSQ drug

Medical treatments may get more expensive for you from next year

Increase in Pharmacy colleges to meet rising demand of Medical Stores

Pharmexcil is seeking candidates for the role of Director

IPC flags safety alert against NSAID Diclofenac

Narcotics Drugs: Team raids Zirakpur Pharmaceuticals firm

Sun Pharma gets CDSCO panel nod for FDC Brinzolamide, Timolol, Pot…

Procedure for registration of Medical Devices: CDSCO

Latest Notifications regarding Pharmaceuticals

For informative videos by The Health Master, click on the below YouTube icon:

YouTube Icon
Telegram
WhatsApp
Facebook
LinkedIn
YouTube Icon
Google-news

Enter your email address:

Delivered by FeedBurner